Overview
Pharmaceutical

Fuso Pharmaceutical Industries,Ltd.

Fuso Pharmaceutical Industries is a Japanese specialty pharmaceutical company focused on the manufacturing and sales of injectable solutions (infusions) and artificial kidney dialysis agents as its core medical pharmaceutical products. The company also provides contract manufacturing services for medical pharmaceuticals and medical devices, alongside a real estate leasing business. With over 80 years of history in producing 'water of life,' the company has established a strong position in dialysis treatment and infusion therapy, and has been recognized as 'Dialysis Drug Development Company of the Year in Asia 2026.'

Market Cap
¥18.0B
US$115M
EV
¥34.4B
US$219M
Stock¥2,109▲+0.05%
US$1 = ¥157.05 (2026-10-22)
LTM EV/EBITDA
6.1
x
LTM EV/EBIT
11.4
x
LTM PER
8.2
x
LTM PBR
0.5
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-25.2%pt
100
Oct 23, 25 – Oct 23, 26StockTOPIX
MC → EV Bridge
18.0BUS$115MMarket Cap26.3BUS$168M+ Debt4.57BUS$29.1M− Cash5.33BUS$34.0M− Inv. Sec.34.4BUS$219MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
49.6US$316M'22/351.0US$325M'23/355.4US$353M'24/360.6US$386M'25/362.3US$397M'26/3
EBITDA 5Y (¥B)
4.48US$28.5M'22/34.69US$29.9M'23/34.23US$26.9M'24/36.49US$41.3M'25/35.26US$33.5M'26/3
Net Income 5Y (¥B)
1.48US$9.44M'22/31.61US$10.2M'23/31.38US$8.77M'24/3-3.29-US$20.9M'25/32.01US$12.8M'26/3
Capital Structure
58%
42%
EquityD/E 0.74xDebt
Liquidity vs Debt 5Y (¥B)▼ Net Debt
CashInv. Sec.Debt
10.4US$66.5M11.7US$74.5M'22/311.0US$70.2M11.4US$72.7M'23/39.04US$57.6M12.7US$81.0M'24/310.6US$67.7M21.3US$136M'25/310.2US$64.8M28.5US$181M'26/3
Shareholders
Top 10 hold 36.2%
1
Budo Kyowakai
7.02%
2
The Master Trust Bank of Japan, Ltd. (Trust Account)
6.60%
3
Shikishima Shinko Co., Ltd.
5.30%
4
Fuso Pharmaceutical Industries,Ltd. Employee Stock Ownership Association
3.84%
5
Sumitomo Mitsui Banking Corporation
3.27%
6
Sumitomo Mitsui Trust Bank, Limited
2.88%
7
Mikio TODA
2.10%
8
Nippon Life Insurance Company
1.87%
9
Nakao Yakuhin Co., Ltd.
1.78%
10
Naigai Kasei Co., Ltd.
1.49%
Management
11 officers
Mikio TODA
Representative Director, President
Apr 1966 Joined Fuso Pharmaceutical Industries Aug 1968 General Manager, Administration Office May 1969 Director Jun 1977 Representative Director, Senior Managing Director Feb 1979 Representative Director, President (current)
1943-03-05
Mikihiro TODA
Representative Director, Senior Managing Director, General Manager, Corporate Planning Department
Jan 2003 Joined Japan Overseas Cooperation Volunteers, Japan International Cooperation Agency (JICA) Apr 2003 Dispatched to the United Republic of Tanzania as Village Development Extension Worker, Japan Overseas Cooperation Volunteers Jul 2006 Appointed Long-term Expert, JICA Mar 2016 Joined Fuso Pharmaceutical Industries Apr 2018 General Manager, Business Development and International Business Promotion Office Jun 2021 Director Jun 2021 General Manager, Management Planning Office, concurrently General Manager, Business Development and International Business Promotion Office Apr 2023 General Manager, Corporate Planning Department (current) Jun 2025 Representative Director, Senior Managing Director (current)
1975-11-01
Junichi OKA
Director, General Manager, Production Headquarters
Apr 1971 Joined Fuso Pharmaceutical Industries Jul 2005 Plant Manager, Joto Plant, Production Department, Production Headquarters Jun 2009 Director (current) Jun 2013 Plant Manager, Ibaraki Plant, Production Department, Production Headquarters Apr 2014 Plant Manager, Ibaraki Plant, Production Headquarters Jul 2019 Plant Manager, Joto Plant, Production Headquarters, concurrently General Manager, Production Control Office Jun 2021 General Manager, Production Headquarters, concurrently General Manager, Production Control Office Apr 2022 General Manager, Production Headquarters (current)
1948-08-20
Masanori ITO
Director, in charge of R&D Center
Apr 1974 Joined Fuso Pharmaceutical Industries Apr 2011 General Manager, R&D Center Jun 2013 Director (current) Jun 2021 In charge of R&D Center (current)
1950-11-22
Hideki OTANI
Director, General Manager, Sales Headquarters
Apr 1987 Joined Fuso Pharmaceutical Industries Apr 2013 Manager, Second Sales Section, Sales Department, Sales Headquarters May 2017 General Manager, Sales Department, Sales Headquarters Jun 2017 Director (current) Oct 2019 General Manager, Sales Coordination Department, Sales Headquarters Jun 2021 General Manager, Sales Headquarters (current)
1965-03-20
Takashi KASHIWAGI
Director
Apr 1976 Joined Osaka City Government Dec 2005 Vice Mayor of Osaka City Apr 2007 Deputy Mayor of Osaka City Apr 2010 Vice President, Osaka City University (public university corporation) Jun 2016 President, Osaka Building Technology Association (general incorporated foundation) Apr 2019 Full-time Executive Director, Tezukayama Gakuin (school corporation) Jul 2020 Managing Director, Tezukayama Gakuin Jun 2021 Outside Director of Fuso Pharmaceutical Industries (current) May 2026 Visiting Professor, Tezukayama Gakuin University (current) Concurrent position: Visiting Professor, Tezukayama Gakuin University
1954-01-02
Yasuhiko WATANABE
Director
Dec 1975 Joined Chuo Kaikei Jimusho Audit Corporation Aug 1982 Registered as Certified Public Accountant Jul 2008 Representative Partner, Koyo Kaikei Sha Audit Corporation Jun 2011 Representative Partner, Pegasus Audit Corporation (now Hibiki Audit Corporation) Jun 2013 Outside Statutory Auditor, K.F.C. Co., Ltd. (current) Jun 2015 Outside Statutory Auditor, MK System Co., Ltd. (current) Jul 2015 Auditor, Ritsumeikan Gakuin (school corporation) Jul 2021 Representative, Yasuhiko Watanabe Certified Public Accountant Office (current) Jun 2023 Outside Director of Fuso Pharmaceutical Industries (current) Concurrent positions: Representative, Yasuhiko Watanabe Certified Public Accountant Office; Outside Statutory Auditor, K.F.C. Co., Ltd.; Outside Statutory Auditor, MK System Co., Ltd.
1952-07-25
Yukari IKENO
Director
Apr 1996 Registered as Attorney-at-law Apr 1996 Joined Eiko Sogo Law Office Jan 2001 Partner, Eiko Sogo Law Office Jan 2003 Member, Eiko Law Corporation (current) Jun 2025 Outside Director of Fuso Pharmaceutical Industries (current) Concurrent position: Member Attorney, Eiko Law Corporation
1966-05-10
Junji KUWATA
Full-time Statutory Auditor
Apr 1978 Joined Fuso Pharmaceutical Industries Apr 2009 Branch Manager, Tokyo Third Branch, Sales Department, Sales Headquarters Jun 2015 Branch Manager, Osaka Branch, Sales Department, Sales Headquarters Oct 2019 Branch Manager, Osaka Branch, Sales Coordination Department, Sales Headquarters Jun 2020 Statutory Auditor (current)
1955-10-21
Etsuo AOMOTO
Statutory Auditor
Apr 1982 Registered as Attorney-at-law Apr 1982 Joined Doko Ryuzo Law Office Apr 1998 Opened Aomoto Etsuo Law Office (current) Jun 2012 Outside Statutory Auditor of Fuso Pharmaceutical Industries (current) Concurrent position: Head, Aomoto Etsuo Law Office
1953-06-25
Takaaki NARASAKI
Statutory Auditor
Apr 1978 Joined Osaka National Tax Bureau Jul 2006 Director, Ikuno Tax Office Jul 2007 Chief, Planning Section, General Affairs Department, Osaka National Tax Bureau Jul 2008 Chief, Corporate Taxation Section, Second Taxation Department, Osaka National Tax Bureau Jul 2011 Director, Higashi Tax Office Sep 2012 Opened Narasaki Takaaki Tax Accountant Office (current) Jun 2023 Outside Statutory Auditor of Fuso Pharmaceutical Industries (current) Concurrent position: Head, Narasaki Takaaki Tax Accountant Office
1952-02-10
Large Shareholding Reports
Sumitomo Mitsui Banking Corporation
2026-06-05
2.95%→2.95%
Annual report (as of 2026-03-31): 3.27%
Sumitomo Mitsui Trust Bank, Limited
2026-06-04
2.60%→2.60%
Annual report (as of 2026-03-31): 2.88%
SMBC Nikko Securities Inc.
2026-02-06
3.23%
Sumitomo Mitsui Trust Bank, Limited
2026-02-05
2.60%→2.60%
Annual report (as of 2026-03-31): 2.88%
Sumitomo Mitsui Trust Bank, Limited
2025-09-19
2.60%→2.60%
Annual report (as of 2026-03-31): 2.88%
Disclosures
No disclosures
Primary Source Filings
TDnet
2026-08-10
Q1 Earnings Flash
FY ending Mar 2027
EDINET
2026-06-23
Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINET
2026-06-05
Large Shareholding Report
EDINET
2026-06-04
Large Shareholding Report
TDnet
2026-02-12
Q3 Earnings Flash
FY ending Mar 2026
EDINET
2026-02-06
Large Shareholding Report
EDINET
2026-02-05
Large Shareholding Report
EDINET
2025-11-12
Semi-Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINET
2025-09-19
Large Shareholding Report
TDnet
2025-08-08
Q1 Earnings Flash
FY ending Mar 2026
EDINET
2025-06-24
Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2025-02-10
Q3 Earnings Flash
FY ending Mar 2025
EDINET
2024-11-12
Semi-Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2024-08-08
Q1 Earnings Flash
FY ending Mar 2025
EDINET
2024-06-25
Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINETAmended
2024-02-13
Amended Securities Registration Statement
EDINET
2024-02-13
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2024-01-17
Securities Registration Statement
EDINET
2023-11-10
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-09
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-06-29
Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2023-02-10
Quarterly Securities Report
Period: Oct 2022 – Dec 2022
EDINET
2022-11-10
Quarterly Securities Report
EDINET
2022-08-09
Quarterly Securities Report
EDINET
2022-06-29
Annual Securities Report
EDINET
2022-02-10
Quarterly Securities Report
EDINET
2021-11-12
Quarterly Securities Report
EDINET
2021-08-11
Quarterly Securities Report
EDINET
2021-06-29
Annual Securities Report
EDINET
2021-02-10
Quarterly Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →